Moody Lynn & Lieberson’s GSK GSK Stock Holding History

Moody Lynn & Lieberson’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-75,904	Closed	-$4.18M	–	244
2021 Q4	$4.18M	Buy	+75,904	New	+$3.95M	0.28%	67
2014 Q3	–	Sell	-88,870	Closed	-$5.94M	–	203
2014 Q2	$5.94M	Sell	88,870 -146	-0.2%	-$9.88K	0.82%	52
2014 Q1	$5.95M	Buy	89,016 +521	+0.6%	+$35.2K	0.86%	52
2013 Q4	$5.91M	Sell	88,495 -682	-0.8%	-$44.2K	0.8%	52
2013 Q3	$5.59M	Sell	89,177 -27,681	-24%	-$1.78M	0.86%	51
2013 Q2	$7.3M	Buy	+116,858	New	+$7.42M	1.28%	26

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Moody Lynn & Lieberson's GSK Position: Q1 2022 in Review

Moody Lynn & Lieberson sold out of GSK (GSK) in Q1 2022, closing a stake of 75,904 shares — an estimated $4.18M sold.

Moody Lynn & Lieberson first reported a position in GSK in Q2 2013 and held it in 6 quarters. The position peaked at $7.3M in Q2 2013. 929 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

Moody Lynn & Lieberson reported no remaining GSK position as of Q1 2022 after selling out during the quarter.
Moody Lynn & Lieberson sold 75,904 GSK shares in Q1 2022, an estimated $4.18M.
Moody Lynn & Lieberson first reported a position in GSK in Q2 2013 and held it in 6 quarters.
Moody Lynn & Lieberson's GSK position peaked at $7.3M in Q2 2013.
929 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on Moody Lynn & Lieberson's 13F filing for Q1 2022, filed 27 Apr 2022.